Results 91 to 100 of about 222 (122)

Upfront blood microRNA test in LDCT-reluctant individuals: insights from the biomild trial. [PDF]

J Exp Clin Cancer Res
Sozzi G, Sabia F, Rolli L, Segale M, Suatoni P, Zanghi A, Ruggirello M, Marchianò A, Boeri M, Pastorino U.   +9 more
europepmc   +1 more source

Innovations in Early Lung Cancer Detection: Tracing the Evolution and Advancements in Screening. [PDF]

J Clin Med
Cotton LB, Bach PB, Cisar C, Schonewolf CA, Tennefoss D, Vachani A, Carter-Bawa L, Zaidi AH.   +7 more
europepmc   +1 more source

A Review of Circulating Tumor DNA (ctDNA) and the Liquid Biopsy in Cancer Diagnosis, Screening, and Monitoring Treatment Response. [PDF]

Med Sci Monit
Parums DV.
europepmc   +1 more source

Advances in translational lung cancer research in 2025: a narrative review. [PDF]

Transl Lung Cancer Res
Xu Y, Kuang Y, Guo Y, Lou Y.
europepmc   +1 more source

From multi-omics to deep learning: advances in cfDNA-based liquid biopsy for multi-cancer screening. [PDF]

Biomark Res
Luo X, Xie S, Hong F, Li X, Wei Y, Zhou Y, Su W, Yang Y, Tang L, Dao F, Cai P, Lin H, Lai H, Lyu H.   +13 more
europepmc   +1 more source

The role of circulating tumor DNA in gynecological cancer management. [PDF]

Front Oncol
Gao M, Yu PY, Li RX, Chen C, Cong XF, Liu ZL.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies

Science, 2021
Enhancing liquid biopsies Liquid biopsies, analyses of cell-free DNA that circulates in the blood, can be used in prenatal testing, oncology, and to monitor organ transplant recipients. Lo et al. review the nongenetic information that can be gleaned from analyses of cell-free DNA, which offers additional ...
Y. M. Dennis Lo, Diana S. C. Han, Peiyong Jiang, Rossa W. K. Chiu   +3 more
openaire   +2 more sources

Fragmentomic analysis of circulating tumor DNA-targeted cancer panels

Annals of Oncology, 2023
The isolation of cell-free DNA (cfDNA) from the bloodstream can be used to detect and analyze somatic alterations in circulating tumor DNA (ctDNA), and multiple cfDNA-targeted sequencing panels are now commercially available for Food and Drug Administration (FDA)-approved biomarker indications to guide treatment.
K T, Helzer, M N, Sharifi, J M, Sperger, Y, Shi, M, Annala, M L, Bootsma, S R, Reese, A, Taylor, K R, Kaufmann, H K, Krause, J L, Schehr, N, Sethakorn, D, Kosoff, C, Kyriakopoulos, M E, Burkard, N R, Rydzewski, M, Yu, P M, Harari, M, Bassetti, G, Blitzer, J, Floberg, M, Sjöström, D A, Quigley, S M, Dehm, A J, Armstrong, H, Beltran, R R, McKay, F Y, Feng, R, O'Regan, K B, Wisinski, H, Emamekhoo, A W, Wyatt, J M, Lang, S G, Zhao   +33 more
openaire   +2 more sources

Fragmentomics of proteins and natural oligopeptides

Biophysics, 2008
The term fragmentomics is grounded and defined. Theoretical structure-function analysis of all possible fragments of a protein molecule was performed under the concept of fragmentomics to determine the regions that could be potential sources of regulatory oligopeptides.
openaire   +2 more sources